Delayed treatment with a tumor necrosis factor alpha blocker associated with worse outcomes in patients with spondyloarthritis: data from the Czech National Registry ATTRA

INTRODUCTION: The administration of biologic disease-modifying antirheumatic drugs, including tumor necrosis factor (TNF)-α inhibitors, is observed to interfere with the disease activity and progression. In this study, we aimed to assess the effectiveness and response predictors of adalimumab (ADA),...

Descripción completa

Detalles Bibliográficos
Autores principales: Milota, Tomas, Hurnakova, Jana, Pavelka, Karel, Kristkova, Zlatuse, Nekvindova, Lucie, Horvath, Rudolf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935402/
https://www.ncbi.nlm.nih.gov/pubmed/35321118
http://dx.doi.org/10.1177/1759720X221081649

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935402/
https://www.ncbi.nlm.nih.gov/pubmed/35321118
http://dx.doi.org/10.1177/1759720X221081649

Ejemplares similares